Skip to main content
Erschienen in: Clinical Research in Cardiology 2/2015

01.02.2015 | Original Paper

Beneficial effects of renal sympathetic denervation on cardiovascular inflammation and remodeling in essential hypertension

verfasst von: Oliver Dörr, Christoph Liebetrau, Helge Möllmann, Felix Mahfoud, Sebastian Ewen, Luise Gaede, Christian Troidl, Jedrzej Hoffmann, Nikolai Busch, Gerald Laux, Jens Wiebe, Timm Bauer, Christian Hamm, Holger Nef

Erschienen in: Clinical Research in Cardiology | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Background

Renal sympathetic denervation (RSD) represents a potential treatment option for certain patients with resistant arterial hypertension (HT). HT is associated with chronic vascular inflammation and remodeling, contributing to progressive vascular damage, and atherosclerosis. The present study aimed to evaluate the influence of RSD on cardiovascular inflammation and remodeling by determining serum levels of interleukin-6 (IL-6), high-sensitive C-reactive protein (hsCRP), matrix metalloproteinases (MMP), and tissue inhibitor of metalloproteinases (TIMP).

Methods

A total of 60 consecutive patients (age 67.9 ± 9.6 years) undergoing RSD were included. A therapeutic response was defined as an office systolic blood pressure (SBP) reduction of >10 mmHg 6 months after RSD. Venous serum samples for measurement of hsCRP, IL-6, MMP-2, MMP-9, and TIMP-1 were collected prior to and 6 months after RSD.

Results

A significant reduction in office SBP of 26.4 mmHg [SBPbaseline 169.3 mmHg (SD 11.3), p < 0.001] was documented 6 months after RSD. The serum levels of hsCRP (p < 0.001) and the pro-inflammatory cytokine IL-6 (p < 0.001) were significantly decreased compared to baseline values. The levels of MMP-9 (p = 0.024) and MMP-2 (p < 0.01) were significantly increased compared to baseline values.

Conclusion

In addition to the effective blood pressure reduction in response to RSD, this study demonstrates a positive effect of RSD on biomarkers reflecting vascular inflammation and remodeling. These results suggest a possible prognostic benefit of RSD in high-risk patients for endothelial dysfunction and cardiovascular remodeling as well as end-organ damage.
Literatur
1.
Zurück zum Zitat Task force for the management of arterial hypertension of the European Society of Cardiology (2007) Guidelines for the management of arterial hypertension. Eur Heart J 28:1462–1536 Task force for the management of arterial hypertension of the European Society of Cardiology (2007) Guidelines for the management of arterial hypertension. Eur Heart J 28:1462–1536
2.
Zurück zum Zitat Mendall MA, Patel P, Asante M, Ballam L, Morris J, Strachan DP, Camm AJ, Northfield TC (1997) Relation of serum cytokine concentrations to cardiovascular risk factors and coronary heart disease. Heart 78:273–277PubMedCentralPubMedCrossRef Mendall MA, Patel P, Asante M, Ballam L, Morris J, Strachan DP, Camm AJ, Northfield TC (1997) Relation of serum cytokine concentrations to cardiovascular risk factors and coronary heart disease. Heart 78:273–277PubMedCentralPubMedCrossRef
3.
Zurück zum Zitat Furumoto T, Saito N, Dong J, Mikami T, Fujii S, Kitabatake A (2002) Association of cardiovascular risk factors and endothelial dysfunction in Japanese hypertensive patients: implications for early athero- sclerosis. Hypertens Res 25:475–480PubMedCrossRef Furumoto T, Saito N, Dong J, Mikami T, Fujii S, Kitabatake A (2002) Association of cardiovascular risk factors and endothelial dysfunction in Japanese hypertensive patients: implications for early athero- sclerosis. Hypertens Res 25:475–480PubMedCrossRef
4.
Zurück zum Zitat Böhm M, Voors A, Ketelslegers JM, Schirmer SH, Turgonyi E, Bramlage P, Zannad F (2011) Biomarkers: optimizing treatment guidance in heart failure. Clin Res Cardiol 100:973–981PubMedCrossRef Böhm M, Voors A, Ketelslegers JM, Schirmer SH, Turgonyi E, Bramlage P, Zannad F (2011) Biomarkers: optimizing treatment guidance in heart failure. Clin Res Cardiol 100:973–981PubMedCrossRef
5.
Zurück zum Zitat Breda L, Di Marzio D, Giannini C, Gaspari S, Nozzi M, Scarinci A, Chiarelli F, Mohn A (2013) (2013Relationship between inflammatory markers, oxidant–antioxidant status and intima-media thickness in prepubertal children with juvenile idiopathic arthritis. Clin Res Cardiol 102:63–71PubMedCrossRef Breda L, Di Marzio D, Giannini C, Gaspari S, Nozzi M, Scarinci A, Chiarelli F, Mohn A (2013) (2013Relationship between inflammatory markers, oxidant–antioxidant status and intima-media thickness in prepubertal children with juvenile idiopathic arthritis. Clin Res Cardiol 102:63–71PubMedCrossRef
6.
Zurück zum Zitat Fernandez-Real JM, Vayreda M, Richart C, Gutierrez C, Broch M, Vendrell J, Ricart W (2001) Circulating interleukin-6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. J Clin Endocrinol Metab 86:1154–1159PubMedCrossRef Fernandez-Real JM, Vayreda M, Richart C, Gutierrez C, Broch M, Vendrell J, Ricart W (2001) Circulating interleukin-6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. J Clin Endocrinol Metab 86:1154–1159PubMedCrossRef
7.
Zurück zum Zitat Lok D, Lok S, de la Porte PBA, Badings E, Lipsic E, van Wijngaarden J, de Boer R, Dvan Veldhuisen DJ, van der Meer P (2013) Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clin Res Cardiol 102:103–111PubMedCrossRef Lok D, Lok S, de la Porte PBA, Badings E, Lipsic E, van Wijngaarden J, de Boer R, Dvan Veldhuisen DJ, van der Meer P (2013) Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clin Res Cardiol 102:103–111PubMedCrossRef
8.
Zurück zum Zitat Fassbach M, Schwartzkopff B (2005) Elevated serum markers for collagen synthesis in patients with hypertrophic cardiomyopathy and diastolic dysfunction. Z Kardiol 94:328–335PubMedCrossRef Fassbach M, Schwartzkopff B (2005) Elevated serum markers for collagen synthesis in patients with hypertrophic cardiomyopathy and diastolic dysfunction. Z Kardiol 94:328–335PubMedCrossRef
9.
Zurück zum Zitat Intengan HD, Schiffrin EL (2000) Structure and mechanical properties of resistance arteries in hypertension. Role of adhesion molecules and extracellular matrix determinants. Hypertension 36:312–318PubMedCrossRef Intengan HD, Schiffrin EL (2000) Structure and mechanical properties of resistance arteries in hypertension. Role of adhesion molecules and extracellular matrix determinants. Hypertension 36:312–318PubMedCrossRef
10.
Zurück zum Zitat Li-Saw-Hee FL, Edmunds E, Blann AD, Beevers DG, Lip GY (2000) Matrix metalloproteinase-9 and tissue inhibitor metallopro- teinase-1 levels in essential hypertension. Relation- ship to left ventricular mass and anti-hypertensive therapy. Int J Cardiol 75:43–47PubMedCrossRef Li-Saw-Hee FL, Edmunds E, Blann AD, Beevers DG, Lip GY (2000) Matrix metalloproteinase-9 and tissue inhibitor metallopro- teinase-1 levels in essential hypertension. Relation- ship to left ventricular mass and anti-hypertensive therapy. Int J Cardiol 75:43–47PubMedCrossRef
11.
Zurück zum Zitat Laurent S (1995) Arterial wall hypertrophy and stiffness in essential hypertensive patients. Hypertension 26:355–362PubMedCrossRef Laurent S (1995) Arterial wall hypertrophy and stiffness in essential hypertensive patients. Hypertension 26:355–362PubMedCrossRef
12.
Zurück zum Zitat Lindsay M, Maxwell P, Dunn FG (2002) TIMP-1: a marker of left ventricular diastolic dysfunction and fibrosis in hypertension. Hypertension 40:136–141PubMedCrossRef Lindsay M, Maxwell P, Dunn FG (2002) TIMP-1: a marker of left ventricular diastolic dysfunction and fibrosis in hypertension. Hypertension 40:136–141PubMedCrossRef
13.
Zurück zum Zitat Madhavan S, Ooi WL, Cohen H, Alderman MH (1994) Relation of pulse pressure and blood pressure reduction to the incidence of myocardial infarction. Hypertension 23:395–401PubMedCrossRef Madhavan S, Ooi WL, Cohen H, Alderman MH (1994) Relation of pulse pressure and blood pressure reduction to the incidence of myocardial infarction. Hypertension 23:395–401PubMedCrossRef
14.
Zurück zum Zitat Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM, American Heart Association Professional Education Committee (2008) Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 117:510–526CrossRef Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM, American Heart Association Professional Education Committee (2008) Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 117:510–526CrossRef
15.
Zurück zum Zitat Lloyd-Jones D, Adams R, Carnethon M (2009) Heart disease and stroke statistics—2009 update: a report from the American heart association statistics committee and stroke statistics subcommittee. Circulation 119:480–486PubMedCrossRef Lloyd-Jones D, Adams R, Carnethon M (2009) Heart disease and stroke statistics—2009 update: a report from the American heart association statistics committee and stroke statistics subcommittee. Circulation 119:480–486PubMedCrossRef
16.
Zurück zum Zitat Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J (2005) Global burden of hypertension: analysis of worldwide data. Lancet 365:217–223PubMedCrossRef Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J (2005) Global burden of hypertension: analysis of worldwide data. Lancet 365:217–223PubMedCrossRef
17.
Zurück zum Zitat Kopp UC, Cicha MZ, Smith LA, Mulder J, Hökfelt T (2007) Renal sympathetic nerve activity modulates afferent renal nerve activity by PGE2-dependent activation of alpha1- and alpha2-adrenoceptors on renal sensory nerve fibers. Am J Physiol Regul Integr Comp Physiol 293:561–572CrossRef Kopp UC, Cicha MZ, Smith LA, Mulder J, Hökfelt T (2007) Renal sympathetic nerve activity modulates afferent renal nerve activity by PGE2-dependent activation of alpha1- and alpha2-adrenoceptors on renal sensory nerve fibers. Am J Physiol Regul Integr Comp Physiol 293:561–572CrossRef
18.
Zurück zum Zitat Hausberg M, Kosch M, Harmelink P, Barenbrock M, Hohage H, Kisters K, Dietl KH, Rahn KH (2002) Sympathetic nerve activity in end-stage renal disease. Circulation 106:1974–1979PubMedCrossRef Hausberg M, Kosch M, Harmelink P, Barenbrock M, Hohage H, Kisters K, Dietl KH, Rahn KH (2002) Sympathetic nerve activity in end-stage renal disease. Circulation 106:1974–1979PubMedCrossRef
19.
Zurück zum Zitat Sobotka PA, Mahfoud F, Schlaich MP, Hoppe UC, Böhm M, Krum H (2011) Sympatho-renal axis in chronic disease. Clin Res Cardiol 100(12):1049–1057PubMedCentralPubMedCrossRef Sobotka PA, Mahfoud F, Schlaich MP, Hoppe UC, Böhm M, Krum H (2011) Sympatho-renal axis in chronic disease. Clin Res Cardiol 100(12):1049–1057PubMedCentralPubMedCrossRef
20.
Zurück zum Zitat Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT, Esler M (2009) Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 373:1275–1281PubMedCrossRef Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT, Esler M (2009) Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 373:1275–1281PubMedCrossRef
21.
Zurück zum Zitat Symplicity HTN-2 Investigators (2010) Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 376:1903–1909CrossRef Symplicity HTN-2 Investigators (2010) Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 376:1903–1909CrossRef
22.
Zurück zum Zitat Mendelsohn FO (2014) Does complete renal denervation translate into superior clinical outcomes? Lessons learned from denervation of accessory renal arteries. Clin Res Cardiol 103:681–683PubMedCentralPubMedCrossRef Mendelsohn FO (2014) Does complete renal denervation translate into superior clinical outcomes? Lessons learned from denervation of accessory renal arteries. Clin Res Cardiol 103:681–683PubMedCentralPubMedCrossRef
23.
Zurück zum Zitat Patel HC, Dhillon PS, Mahfoud F, Lindsay AC, Hayward C, Ernst S, Lyon AR, Rosen SD, di Mario C (2014) The biophysics of renal sympathetic denervation using radiofrequency energy. Clin Res Cardiol 103(5):337–344PubMedCrossRef Patel HC, Dhillon PS, Mahfoud F, Lindsay AC, Hayward C, Ernst S, Lyon AR, Rosen SD, di Mario C (2014) The biophysics of renal sympathetic denervation using radiofrequency energy. Clin Res Cardiol 103(5):337–344PubMedCrossRef
24.
Zurück zum Zitat Vogel B, Kirchberger M, Zeier M, Stoll F, Meder B, Saure D, Andrassy M, Mueller OJ, Hardt S, Schwenger V, Strothmeyer A, Katus HA, Blessing E (2014) Renal sympathetic denervation therapy in the real world: results from the Heidelberg registry. Clin Res Cardiol 103(2):117–124PubMedCrossRef Vogel B, Kirchberger M, Zeier M, Stoll F, Meder B, Saure D, Andrassy M, Mueller OJ, Hardt S, Schwenger V, Strothmeyer A, Katus HA, Blessing E (2014) Renal sympathetic denervation therapy in the real world: results from the Heidelberg registry. Clin Res Cardiol 103(2):117–124PubMedCrossRef
25.
26.
Zurück zum Zitat Dörr O, Liebetrau C, Möllmann H, Achenbach S, Sedding D, Szardien S, Willmer M, Rixe J, Troidl C, Elsässer A, Hamm C, Nef HM (2013) Renal sympathetic denervation does not aggravate functional or structural renal damage. J Am Coll Cardiol 61:479–480PubMedCrossRef Dörr O, Liebetrau C, Möllmann H, Achenbach S, Sedding D, Szardien S, Willmer M, Rixe J, Troidl C, Elsässer A, Hamm C, Nef HM (2013) Renal sympathetic denervation does not aggravate functional or structural renal damage. J Am Coll Cardiol 61:479–480PubMedCrossRef
27.
Zurück zum Zitat Dörr O, Liebetrau C, Möllmann H, Gaede L, Troidl C, Rixe J, Hamm C, Nef H (2014) Soluble fms-like tyrosine kinase-1 and endothelial adhesion molecules (intercellular cell adhesion molecule-1 and vascular cell adhesion molecule-1) as predictive markers for blood pressure reduction after renal sympathetic denervation. Hypertension 63(5):984–990PubMedCrossRef Dörr O, Liebetrau C, Möllmann H, Gaede L, Troidl C, Rixe J, Hamm C, Nef H (2014) Soluble fms-like tyrosine kinase-1 and endothelial adhesion molecules (intercellular cell adhesion molecule-1 and vascular cell adhesion molecule-1) as predictive markers for blood pressure reduction after renal sympathetic denervation. Hypertension 63(5):984–990PubMedCrossRef
28.
Zurück zum Zitat Mahfoud F, Ukena C, Schmieder RE, Cremers B, Rump LC, Vonend O, Weil J, Schmidt M, Hoppe UC, Zeller T, Bauer A, Ott C, Blessing E, Sobotka PA, Krum H, Schlaich M, Esler M, Böhm M (2013) Response to letter regarding article, “ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension”. Circulation 128:132–140PubMedCrossRef Mahfoud F, Ukena C, Schmieder RE, Cremers B, Rump LC, Vonend O, Weil J, Schmidt M, Hoppe UC, Zeller T, Bauer A, Ott C, Blessing E, Sobotka PA, Krum H, Schlaich M, Esler M, Böhm M (2013) Response to letter regarding article, “ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension”. Circulation 128:132–140PubMedCrossRef
29.
Zurück zum Zitat Brasier AR, Recinos A III, Eledrisi MS (2002) Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol 22:1257–1266PubMedCrossRef Brasier AR, Recinos A III, Eledrisi MS (2002) Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol 22:1257–1266PubMedCrossRef
30.
Zurück zum Zitat Sliwa K, Ojji D, Bachelier K, Böhm M, Damasceno A, Stewart S (2014) Hypertension and hypertensive heart disease in African women. Clin Res Cardiol 103(7):515–523PubMedCrossRef Sliwa K, Ojji D, Bachelier K, Böhm M, Damasceno A, Stewart S (2014) Hypertension and hypertensive heart disease in African women. Clin Res Cardiol 103(7):515–523PubMedCrossRef
31.
Zurück zum Zitat Schiffrin EL, Touyz RM (2004) From bedside to bench to bedside: role of renin- angiotensin-aldosterone system in remodeling of resistance arteries in hypertension. Am J Physiol Heart Circ Physiol 287:H435–H446PubMedCrossRef Schiffrin EL, Touyz RM (2004) From bedside to bench to bedside: role of renin- angiotensin-aldosterone system in remodeling of resistance arteries in hypertension. Am J Physiol Heart Circ Physiol 287:H435–H446PubMedCrossRef
32.
Zurück zum Zitat Touyz RM, Schiffrin EL (2004) Reactive oxygen species in vascular biology: implications in hypertension. Histochem Cell Biol 122:339–352PubMedCrossRef Touyz RM, Schiffrin EL (2004) Reactive oxygen species in vascular biology: implications in hypertension. Histochem Cell Biol 122:339–352PubMedCrossRef
33.
Zurück zum Zitat Schiffrin EL (2005) Vascular endothelin in hypertension. Vasc Pharmacol 43:19–29CrossRef Schiffrin EL (2005) Vascular endothelin in hypertension. Vasc Pharmacol 43:19–29CrossRef
34.
Zurück zum Zitat Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, Maseri A (1994) The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 331:417–424PubMedCrossRef Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, Maseri A (1994) The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 331:417–424PubMedCrossRef
35.
Zurück zum Zitat Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH (1997) Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336:973–976PubMedCrossRef Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH (1997) Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336:973–976PubMedCrossRef
36.
Zurück zum Zitat Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH (1998) Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 98:731–733PubMedCrossRef Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH (1998) Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 98:731–733PubMedCrossRef
37.
Zurück zum Zitat Chae CU, Lee RT, Rifai N, Ridker PM (2001) Blood pressure and inflammation in apparently healthy men. Hypertension 38:399–403PubMedCrossRef Chae CU, Lee RT, Rifai N, Ridker PM (2001) Blood pressure and inflammation in apparently healthy men. Hypertension 38:399–403PubMedCrossRef
38.
Zurück zum Zitat Mitrovic V, Klein HH, Krekel N, Kreuzer J, Fichtlscherer S, Schirmer A, Paar WD, Hamm CW (2005) Influence of the angiotensin converting enzyme inhibitor ramipril on high-sensitivity C-reactive protein (hs-CRP) in patients with documented atherosclerosis. Z Kardiol 94(5):336–342PubMedCrossRef Mitrovic V, Klein HH, Krekel N, Kreuzer J, Fichtlscherer S, Schirmer A, Paar WD, Hamm CW (2005) Influence of the angiotensin converting enzyme inhibitor ramipril on high-sensitivity C-reactive protein (hs-CRP) in patients with documented atherosclerosis. Z Kardiol 94(5):336–342PubMedCrossRef
39.
Zurück zum Zitat Engström G, Janzon L, Berglund G, Lind P, Stavenow L, Hedblad B, Lindgärde F (2002) Blood pressure increase and incidence of hypertension in relation to inflammation-sensitive plasma proteins. Arterioscler Thromb Vasc Biol 22:2054–2058PubMedCrossRef Engström G, Janzon L, Berglund G, Lind P, Stavenow L, Hedblad B, Lindgärde F (2002) Blood pressure increase and incidence of hypertension in relation to inflammation-sensitive plasma proteins. Arterioscler Thromb Vasc Biol 22:2054–2058PubMedCrossRef
40.
Zurück zum Zitat Dollery CM, McEwan JR, Henney AM (1995) Matrix metalloproteinases and cardiovascular disease. Circ Res 77:863–868PubMedCrossRef Dollery CM, McEwan JR, Henney AM (1995) Matrix metalloproteinases and cardiovascular disease. Circ Res 77:863–868PubMedCrossRef
41.
Zurück zum Zitat Weber KT, Sun Y, Guarda E, Katwa LC, Ratajska A, Cleutjens JP, Zhou G (1995) Myocardial fibrosis in hypertensive heart disease: an overview of potential regulatory mechanisms. Eur Heart J 16(suppl C):24–28PubMedCrossRef Weber KT, Sun Y, Guarda E, Katwa LC, Ratajska A, Cleutjens JP, Zhou G (1995) Myocardial fibrosis in hypertensive heart disease: an overview of potential regulatory mechanisms. Eur Heart J 16(suppl C):24–28PubMedCrossRef
42.
Zurück zum Zitat Galis ZS, Sukluva GK, Lark MW, Libby P (1994) Increased expression of matrix metalloproteinases and matrix degrading activity in vulner- able regions of human atherosclerotic plaques. J Clin Invest 94:2493–2503PubMedCentralPubMedCrossRef Galis ZS, Sukluva GK, Lark MW, Libby P (1994) Increased expression of matrix metalloproteinases and matrix degrading activity in vulner- able regions of human atherosclerotic plaques. J Clin Invest 94:2493–2503PubMedCentralPubMedCrossRef
43.
Zurück zum Zitat Laviades C, Varo N, Fernández J, Mayor G, Gil MJ, Monreal I, Díez J (1998) Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation 98:535–540PubMedCrossRef Laviades C, Varo N, Fernández J, Mayor G, Gil MJ, Monreal I, Díez J (1998) Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation 98:535–540PubMedCrossRef
44.
Zurück zum Zitat Picard F, Brehm M, Fassbach M, Pelzer B, Scheuring S, Küry P, Strauer BE, Schwartzkopff B (2006) Increased cardiac mRNA expression of matrix metalloproteinase-1 (MMP-1) and its inhibitor (TIMP-1) in DCM patients. Clin Res Cardiol 95(5):261–269PubMedCrossRef Picard F, Brehm M, Fassbach M, Pelzer B, Scheuring S, Küry P, Strauer BE, Schwartzkopff B (2006) Increased cardiac mRNA expression of matrix metalloproteinase-1 (MMP-1) and its inhibitor (TIMP-1) in DCM patients. Clin Res Cardiol 95(5):261–269PubMedCrossRef
45.
Zurück zum Zitat Brilla CG, Moderer S, Salge U, Heidmann HH (1994) Collagenolytic activity in left ventricular endomyocardial biopsies of patients with hypertensive heart disease or hypertrophic cardiomyopathy. Circulation 90(suppl I):I-264 Brilla CG, Moderer S, Salge U, Heidmann HH (1994) Collagenolytic activity in left ventricular endomyocardial biopsies of patients with hypertensive heart disease or hypertrophic cardiomyopathy. Circulation 90(suppl I):I-264
46.
Zurück zum Zitat Li-Saw-Hee FL, Edmunds E, Blann AD, Beevers DG, Lip GY (2000) Matrix metalloproteinase-9 and tissue inhibitor metallopro- teinase-1 levels in essential hypertension. Relation- ship to left ventricular mass and anti-hypertensive therapy. Int J Cardiol 75:43–47PubMedCrossRef Li-Saw-Hee FL, Edmunds E, Blann AD, Beevers DG, Lip GY (2000) Matrix metalloproteinase-9 and tissue inhibitor metallopro- teinase-1 levels in essential hypertension. Relation- ship to left ventricular mass and anti-hypertensive therapy. Int J Cardiol 75:43–47PubMedCrossRef
47.
Zurück zum Zitat Intengan HD, Schiffrin EL (2000) Structure and mechanical properties of resistance arteries in hypertension. Role of adhesion molecules and extracellular matrix determinants. Hypertension 36:312–318PubMedCrossRef Intengan HD, Schiffrin EL (2000) Structure and mechanical properties of resistance arteries in hypertension. Role of adhesion molecules and extracellular matrix determinants. Hypertension 36:312–318PubMedCrossRef
48.
Zurück zum Zitat Mancia G, Parati G (2004) Office compared with ambulatory blood pressure in assessing response to antihypertensive treatment: a meta-analysis. J Hypertens 22:435–445PubMedCrossRef Mancia G, Parati G (2004) Office compared with ambulatory blood pressure in assessing response to antihypertensive treatment: a meta-analysis. J Hypertens 22:435–445PubMedCrossRef
49.
Zurück zum Zitat Sun M, Chen M, Dawood F, Zurawska U, Li JY, Parker T, Kassiri Z, Kirshenbaum LA, Arnold M, Khokha R, Liu PP (2007) Tumor necrosis factor-alpha mediates cardiac remodeling and ventricular dys- function after pressure overload state. Circulation 115:1398e407 Sun M, Chen M, Dawood F, Zurawska U, Li JY, Parker T, Kassiri Z, Kirshenbaum LA, Arnold M, Khokha R, Liu PP (2007) Tumor necrosis factor-alpha mediates cardiac remodeling and ventricular dys- function after pressure overload state. Circulation 115:1398e407
50.
Zurück zum Zitat Swynghedauw B (1999) Molecular mechanisms of myocardial remodeling. Physiol Rev 79:215–262PubMed Swynghedauw B (1999) Molecular mechanisms of myocardial remodeling. Physiol Rev 79:215–262PubMed
51.
Zurück zum Zitat Radauceanu A, Ducki C, Virion JM, Rossignol P, Mallat Z, McMurray J, Veldhuisen DJ, Tavazzi L, Mann DL, Capiaumont-Vin J, Li M, Hanriot D, Zannad F (2008) Extracellular Matrix Turnover and Inflammatory Markers Independently Predict Functional Status and Outcome in Chronic Heart Failure. J Cardiac Fail 14:467–474CrossRef Radauceanu A, Ducki C, Virion JM, Rossignol P, Mallat Z, McMurray J, Veldhuisen DJ, Tavazzi L, Mann DL, Capiaumont-Vin J, Li M, Hanriot D, Zannad F (2008) Extracellular Matrix Turnover and Inflammatory Markers Independently Predict Functional Status and Outcome in Chronic Heart Failure. J Cardiac Fail 14:467–474CrossRef
Metadaten
Titel
Beneficial effects of renal sympathetic denervation on cardiovascular inflammation and remodeling in essential hypertension
verfasst von
Oliver Dörr
Christoph Liebetrau
Helge Möllmann
Felix Mahfoud
Sebastian Ewen
Luise Gaede
Christian Troidl
Jedrzej Hoffmann
Nikolai Busch
Gerald Laux
Jens Wiebe
Timm Bauer
Christian Hamm
Holger Nef
Publikationsdatum
01.02.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Clinical Research in Cardiology / Ausgabe 2/2015
Print ISSN: 1861-0684
Elektronische ISSN: 1861-0692
DOI
https://doi.org/10.1007/s00392-014-0773-4

Weitere Artikel der Ausgabe 2/2015

Clinical Research in Cardiology 2/2015 Zur Ausgabe

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.